Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)

Study to Evaluate the Efficacy and Safety of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)

This study is a prospective study, randomized, using control, open-label, single-center to evaluate the efficacy and safety of EASYEF® in acute wound (split-thickness skin graft donor site). A total of 10 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test cohorts in a ratio of 1:1:1.

Study Overview

• Status: Completed
• Conditions: Skin Graft Scar; Split-Thickness Skin Graft (STSG)
• Intervention / Treatment: Drug: rhEGF

Detailed Description

This study was intended to determine the effect of EGF on acute wounds such as trauma, surgical wounds and burns. But in this study, skin graft donor site wounds were used because they were the most representative for acute wounds and the depth and extent of the wounds could be controlled. EGF is known pharmacologically to accelerate epithelial cell proliferation, fibroblast cells and endothelial cells. Giving EGF in acute wounds is expected to accelerate wound healing and improve patient quality of life.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Indonesia
  • DKI Jakarta
    • Central Jakarta, DKI Jakarta, Indonesia, 10410
      • RSPAD Gatot Soebroto

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients who have donor wounds on the vertical (upper and lower) lines of the thigh through skin grafted surgery due to trauma, ulcers, burns, and incisional surgical defects.
• The size of the donor follows the standard and the distance between the two skin transplants is at least 2 cm.
• Patients who are expected to be able to successfully complete or benefit from this examination are based on appropriate medical assessment.
• Patients is willing to be treated 7 days as inpatient and treated as outpatient for maximum 7 days with homecare nurse visit.
• Patients is willing to stay near the hospital and visit the hospital after the donor site wound is declared healed by doctor.
• Patients who decided and agreed in writing to enroll in this study at their own will.
• Patients aged 18 and up

Exclusion Criteria:

• Patients with different skin donor site can influence the results of the study.
• Patients who have other diseases that can interfere with wound healing such as immunosuppressive, metabolic collagen, peripheral vascular obstructive disease (PAOD), systemic vasculitis, and others.
• Patients have the talent for keloid formation.
• Patients have uncontrolled diabetes and diabetes with complications.
• Patients with liver disease, kidney disease, and other serious diseases that can affect this study.
• Patients who are deemed difficult to carry out the study by the investigators.
• Women who are pregnant, lactation or not using reliable methods of contraception and who do not consent to continue contraception for the duration of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cohort 1; EASYEF® + moist gauze EASYEF® is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.; Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.	Drug: rhEGF; EASYEF® spray 50 mcg, sprayed twice a day for 14 days.; Other Names: EASYEF®
Active Comparator: Cohort 2; EASYEF® + tulle gauze + moist gauze EASYEF® is applied directly on the wound surface then tulle gauze and moist gauze is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.; Tulle gauze + moist gauze Tulle gauze is applied directly on the wound surface then moist dressing is used as primary dressing before covered with dry gauze. All dressings are fixed with elastic bandage.	Drug: rhEGF; EASYEF® spray 50 mcg, sprayed twice a day for 14 days.; Other Names: EASYEF®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the wound healing time of each skin graft donor site	The definition of 'wound healing' is when there is no more exudate in the skin graft donor and the skin is covered with epithelial tissue in a milky light pink color and there is no pain. Healing time (morning or afternoon) evaluation and pain scale (11-point NRS (Numeric Rating Scale); 0 = No pain, 5 = Moderate pain, and 10 = Worst possible pain) will be assessed.	14 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events	In order to confirm the adverse events (AE), it is confirmed through the questionnaire of investigators and the physical examination. If an adverse event occurs, record the timing of the adverse event, the duration, the extent of the adverse event, and the causal relationship.	14 days
Photograph evaluation	During the change of dressing in the morning and evening, photograph was taken to evaluate the re-epithelization improvement.	14 days

Collaborators and Investigators

• Sponsor: PT. Daewoong Infion
• Collaborators: Equilab International

Study record dates

Study Major Dates

• Study Start (Actual): July 19, 2019
• Primary Completion (Actual): March 1, 2020
• Study Completion (Actual): April 8, 2020

Study Registration Dates

• First Submitted: April 6, 2022
• First Submitted That Met QC Criteria: April 17, 2022
• First Posted (Actual): April 19, 2022

Study Record Updates

• Last Update Posted (Actual): July 22, 2022
• Last Update Submitted That Met QC Criteria: July 19, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Skin graft; Epidermal Growth Factor; EGF; rhEGF; recombinant human Epidermal Growth Factor; Acute wound
• Other Study ID Numbers: DW_EGFCS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No